BRKR Stock Recent News
BRKR LATEST HEADLINES
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Bruker Corporation (NASDAQ:BRKR ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Joe Kostka - Associate Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Josh Waldman - Cleveland Research Operator Good day. And welcome to the Bruker Corporation Second Quarter 2024 Earnings Call.
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.50 per share a year ago.
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: “Our teams delivered excellent revenue growth in the second quarter and a solid first half of 2024, despite soft general market conditions. Our well above-market organic growth is driven by Bruker's differentiated innovation engine, as well as our multi-year transformatio.
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.